Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, randomized, two-arm, open-label, comparative phase II trial of
Mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FRα) high recurrent ovarian
cancer eligible for platinum-based chemotherapy.